Mr. DeLuccia is our co-founder and Executive Chairman. Prior to our IPO, Mr. DeLuccia served as our Managing Partner and Director since February 2018. Previously, Mr. DeLuccia was the Executive Chairman of Dipexium Pharmaceuticals (Nasdaq: DPRX), a pharmaceutical company focused on antibiotic drug development, from February 2010 until its sale to PLx Pharma Inc. (Nasdaq: PLXP) in a merger valued at $69 million in April 2017. Previously, from 2004 to 2009, Mr. DeLuccia served in several capacities at MacroChem, a development-stage, publicly traded pharmaceutical company using topical drug delivery technology for products in dermatology, podiatry, urology and cancer, including as Chairman of the board of directors, President and Chief Executive Officer. Prior to joining MacroChem, Mr. DeLuccia served as President and Chief Executive Officer of Immunomedics, Inc., a publicly-traded biopharmaceutical company focused on antibody-based therapeutic products and diagnostic imaging for cancer and infectious diseases. Mr. DeLuccia also served as President of Sterling Winthrop, Inc. (or Sterling Winthrop) (as an independent corporation and then as subsidiary of Eastman Kodak), and subsequently, upon acquisition, the U.S. subsidiary of Sanofi-Aventis (or Sanofi) and currently serves as a member of the board of directors of IBEX Technologies Inc., which manufactures and markets proprietary enzymes (heparinases and chondroitinases) for use in pharmaceutical research and Heparinase I, used in many leading hemostasis monitoring devices. Mr. DeLuccia began his career as a pharmaceutical sales representative for Pfizer, Inc. (or Pfizer) and progressed to Director of Marketing, Pfizer Laboratories Division, and to Vice President Marketing and Sales Operations for Pfizer’s Roerig Division. Mr. DeLuccia received a Bachelor of Business Administration with a concentration in Marketing and a Master’s Degree in Business Administration from Iona College. Mr. DeLuccia was selected to serve as Chairman of our board of directors because of his extensive executive leadership and experience in the pharmaceutical industry.
How old is Robert J. DeLuccia?
How do I contact Robert J. DeLuccia?
Has Robert J. DeLuccia been buying or selling shares of Acurx Pharmaceuticals?
Robert J. DeLuccia has not been actively trading shares of Acurx Pharmaceuticals during the last quarter. Most recently, on Friday, November 19th, Robert J. Deluccia bought 5,034 shares of Acurx Pharmaceuticals stock. The stock was acquired at an average cost of $4.90 per share, with a total value of $24,666.60. Learn More on Robert J. DeLuccia's trading history.
Who are Acurx Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Acurx Pharmaceuticals?
In the last twelve months, Acurx Pharmaceuticals insiders bought shares 2 times. They purchased a total of 73,892 shares worth more than $74,630.92. The most recent insider tranaction occured on January, 6th when Director Joseph C Scodari bought 24,631 shares worth more than $24,877.31. Insiders at Acurx Pharmaceuticals own 29.6% of the company.
Learn More about insider trades at Acurx Pharmaceuticals. Information on this page was last updated on 1/6/2025.
